Sypharma

Sypharma and Vaxine Pty Ltd COVID-19 Partnership

Sypharma partners with Vaxine Pty Ltd. to manufacture COVID-19 vaccine product.

End-to-end Australian capability

Around the world, pharmaceutical manufacturers and researchers’ objectives remain the same.

To protect the safety of our community and to supply essential medicines for those who need them. This is our unique responsibility as an industry.

Sypharma is honoured to announce that we have collaborated with Vaxine Pty Ltd to manufacture a first in human vaccine and adjuvant against the CoVID 19 pandemic.

Vaxine’s COVID19 vaccine using recombinant spike protein together with Advax-CpG55.2 adjuvant officially went into human trials yesterday – meeting their ambitious 30 June 2020 deadline set months ago.

Unlocking resources

Collaboration & Potential

We work together with innovative biotech developers to your drug production destination means the world to us, and our dedicated team of experts will support and guide you from the earliest stage of development through commercialization and beyond.

Filter resources by :
  • Clinical Development of SpikoGen®

    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.

    Read Fact Sheet
  • Ensuring Efficacy and Safety

    The Critical Role of Pharmaceutical Cold Chain Transportation

    Read Fact Sheet
  • University of Queensland partners with Sypharma

    Sypharma partners with The University of Queensland for the manufacture of their CoVID-19 Vaccine Product.

    Read Press Release
  • Technovalia, Sypharma and BioNet announce the establishment of Genetis

    Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines.

    Read Press Release
LOAD MORE RESOURCES

Since 2005 unlocking healthier futures.